ClinicalTrials.gg
CompletedNCT07347548Updated Aug 12, 2026

A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants

A Phase 1 interventional study of GRT6019 in Duchenne Muscular Dystrophy (DMD), sponsored by Grünenthal GmbH. Completed at 1 site in France. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Grünenthal GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies in Muscular Dystrophy, Duchenne with a site in France — 11 open to participants now, 13 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · France.

Enrollment
37th of 50
24 · median 83
Started
2026
with 4 others
Phase 1
4 of 66
none open now
Registered
63rd of 66
by date

Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, this one is the 37th largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2026, is one of 4 in phase 1, and was the 63rd registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

11 of the 66 studies in Muscular Dystrophy, Duchenne with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Muscular Dystrophy, Duchenne with a site in France, or all of them as a file.
02

Study summary

The purpose of this trial is to assess the safety, tolerability, and PK of 3 doses of GRT6019 in healthy male participants.

This Phase I trial will be a multiple dose trial in healthy male participants with administration of GRT6019 in 3 cohorts.

For each participant, the trial consists of a Screening Period of up to 28 days, a 4 week Treatment Period (including a 2-week clinic stay and 2 weeks in an outpatient setting), and a 5 week Follow-up Period.

Read the detailed description

There are 8 participants planned per cohort to ensure sufficient sample size for a reliable estimate of PK parameters.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  1. Participant must be male, 18 to 55 years of age (inclusive) at the time of signing the form and affiliated to the social security system.
  2. Participant must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  3. Participant must sign the informed consent form before any trial-related assessments.
  4. The participant is in good health as determined by the medical history, physical examination, 12-lead , vital signs (heart rate, respiratory rate, systolic and diastolic blood pressure [BP]), body temperature, and clinical laboratory parameters (clinical chemistry, hematology, coagulation, and urinalysis) without (per investigator judgement) deviations from reference ranges unless further specified in the exclusion criteria. The population of this clinical trial is healthy volunteer participants.

Main Exclusion Criteria:

  1. Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, comparator, rescue medication, or any ingredients therein, or may affect the interpretation of the results, or may render the participant at high risk from treatment complications/ participation in the study unsafe
  2. Major surgical procedure, within 3 months prior to ICF signing, or anticipation of need for a major surgical procedure during the trial
  3. Clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, or immunological disorder(s)
  4. Regularly uses any medication, including herbal remedies or over-the-counter medication within 2 weeks before screening into this trial and anticipated use during the trial
  5. Concurrent enrollment in another clinical trial, unless it is an observational (non interventional) clinical trial or during the follow-up period of an interventional trial
  6. Recent participation in another clinical trial with an IMP administered within 30 days before Day 1 or within 5 times the elimination half-life of the IMP, whichever is longer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    GRT6019: Cohort 1

    4 weeks dosing with GRT6019 low dose once a day \[QD\]

    Drug: GRT6019

  • Experimental
    GRT6019: Cohort 2

    4 weeks dosing with GRT6019 medium dose once a day \[QD\]

    Drug: GRT6019

  • Experimental
    GRT6019: Cohort 3

    4 weeks dosing with GRT6019 higher dose once a day \[QD\]

    Drug: GRT6019

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Assessment of safety and tolerability of GRT6019 following 4 weeks of treatment

    Time frame: Through study completion, an average of 4 Weeks

  2. Number of participants with Serious Adverse Events (SAEs)

    Assessment of safety and tolerability of GRT6019 following 4 weeks of treatment

    Time frame: Through study completion, an average of 4 Weeks

  3. Number of participants with AEs leading to discontinuation

    Assessment of safety and tolerability of GRT6019 following 4 weeks of treatment

    Time frame: Through study completion, an average of 4 Weeks

  4. Number of participants with AEs related to investigational medicinal product [IMP]

    Assessment of safety and tolerability of GRT6019 following 4 weeks of treatment

    Time frame: Through study completion, an average of 4 Weeks

Secondary outcomes

  1. Area under the concentration-time curve over the dosing interval (AUCtau)

    Assessment of the pharmacokinetics (PK) of GRT6019 following 4 weeks of treatment, including dose proportionality assessment and investigation of steady state attainment

    Time frame: Following the first dose (Day 1), then at Day 14, and after the last dose (Day 28)

  2. Maximum observed concentration (Cmax)

    Assessment of the pharmacokinetics (PK) of GRT6019 following 4 weeks of treatment, including dose proportionality assessment and investigation of steady state attainment

    Time frame: Following the first dose (Day 1), then at Day 14, and after the last dose (Day 28)

07

Study locations

1 site
  • Biotrial Clinical Pharmacology Unit
    Rennes, 35042, France
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Jun 2026, 5 months.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 16, 2026
StartActual
Jan 6, 2026
Primary completionActual
Jun 9, 2026
CompletionActual
Jun 9, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07347548
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jan 6, 2026
Primary completion
Jun 9, 2026
Completion
Jun 9, 2026
Last update
Aug 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegacorat

Start the discussion